Literature DB >> 11701929

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

K A Conway1, J C Rochet, R M Bieganski, P T Lansbury.   

Abstract

The substantia nigra in Parkinson's disease (PD) is depleted of dopaminergic neurons and contains fibrillar Lewy bodies comprising primarily alpha-synuclein. We screened a library to identify drug-like molecules to probe the relation between neurodegeneration and alpha-synuclein fibrilization. All but one of 15 fibril inhibitors were catecholamines related to dopamine. The inhibitory activity of dopamine depended on its oxidative ligation to alpha-synuclein and was selective for the protofibril-to-fibril conversion, causing accumulation of the alpha-synuclein protofibril. Adduct formation provides an explanation for the dopaminergic selectivity of alpha-synuclein-associated neurotoxicity in PD and has implications for current and future PD therapeutic and diagnostic strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701929     DOI: 10.1126/science.1063522

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  334 in total

1.  Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery.

Authors:  John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

2.  Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration.

Authors:  Peter Teismann; Kim Tieu; Dong-Kug Choi; Du-Chu Wu; Ali Naini; Stéphane Hunot; Miquel Vila; Vernice Jackson-Lewis; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

Review 3.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

4.  Differentiating Alzheimer disease-associated aggregates with small molecules.

Authors:  Nicolette S Honson; Ronald L Johnson; Wenwei Huang; James Inglese; Christopher P Austin; Jeff Kuret
Journal:  Neurobiol Dis       Date:  2007-07-28       Impact factor: 5.996

5.  Exosomes-associated neurodegeneration and progression of Parkinson's disease.

Authors:  Isabella Russo; Luigi Bubacco; Elisa Greggio
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

6.  Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson's disease.

Authors:  Małgorzata Pokrzywa; Katarzyna Pawełek; Weronika Elżbieta Kucia; Szymon Sarbak; Erik Chorell; Fredrik Almqvist; Pernilla Wittung-Stafshede
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

7.  Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells.

Authors:  Francisco J Diaz-Corrales; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Nobutaka Hattori; Norio Ogawa
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

8.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).

Authors:  Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

9.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

Review 10.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.